The Binge Eating Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Binge Eating Disorder. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Binge Eating Disorder by 16 companies/universities/institutes. The top development phase for Binge Eating Disorder is preclinical with eight drugs in that stage. The Binge Eating Disorder pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Binge Eating Disorder pipeline products market are: Chronos Therapeutics, Tryp Therapeutics and Bright Minds Biosciences.
The key targets in the Binge Eating Disorder pipeline products market include Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1), Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2), and Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3).
The key mechanisms of action in the Binge Eating Disorder pipeline product include Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Antagonist with four drugs in Preclinical. The Binge Eating Disorder pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Binge Eating Disorder pipeline products market including Small Molecule, and Synthetic Peptide.
Binge Eating Disorder overview
Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown, but family history, biological factors, long-term dieting, and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control, and experiencing depression and anxiety. Treatment includes psychotherapy, medication,s and behavioral weight-loss programs.
For a complete picture of Binge Eating Disorder’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
